• Treatment with Encorafenib plus Cetuximab is one standard option of care in patients with BRAF V600E-mutated (MT) metastatic colorectal cancer (mCRC). • Treatment of oligometastatic disease in BRAFV600E MT CRC remains a topic of debate. • Here, we present the case of a patient with oligometastatic lymph nodes-only involvement treated with target therapy and loco-regional treatment.
Treatment of Oligometastatic BRAFV600E Mutant Colorectal Cancer: Learning From a Clinical Case / R.M. Marsicano, L.B.B.. - In: CLINICAL COLORECTAL CANCER. - ISSN 1533-0028. - 24:3(2025 Sep), pp. 410-414. [10.1016/j.clcc.2025.03.003]
Treatment of Oligometastatic BRAFV600E Mutant Colorectal Cancer: Learning From a Clinical Case
R.M. MarsicanoPrimo
;L. Boscolo BieloSecondo
;E.G. Rocco;G. Curigliano;
2025
Abstract
• Treatment with Encorafenib plus Cetuximab is one standard option of care in patients with BRAF V600E-mutated (MT) metastatic colorectal cancer (mCRC). • Treatment of oligometastatic disease in BRAFV600E MT CRC remains a topic of debate. • Here, we present the case of a patient with oligometastatic lymph nodes-only involvement treated with target therapy and loco-regional treatment.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1533002825000301-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
782.75 kB
Formato
Adobe PDF
|
782.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
